Revision as of 16:50, 17 December 2024 editMo18ekula (talk | contribs)248 editsNo edit summary← Previous edit | Latest revision as of 22:09, 19 December 2024 edit undoBearcat (talk | contribs)Autopatrolled, Administrators1,564,929 edits WP:DRAFTNOCAT | ||
(3 intermediate revisions by one other user not shown) | |||
Line 58: | Line 58: | ||
| StdInChIKey = DITYEPYMBCHKLF-UHFFFAOYSA-N | | StdInChIKey = DITYEPYMBCHKLF-UHFFFAOYSA-N | ||
}} | }} | ||
Dazadrol is an antidepressant.<ref> Schmitt H, Petillot N. Propriétés pharmacologiques d'un nouvel antidépresseur potentiel: le ((p-chlorophényl)-2-(pyridyl)-hydroxyméthyl) imidazoline (SCH 12.650 . Therapie. 1971 Jul-Aug;26(4):805-21. French. PMID: 5119131.</ref> | Dazadrol is an antidepressant first quoted in the literature in 1971.<ref> Schmitt H, Petillot N. Propriétés pharmacologiques d'un nouvel antidépresseur potentiel: le ((p-chlorophényl)-2-(pyridyl)-hydroxyméthyl) imidazoline (SCH 12.650 . Therapie. 1971 Jul-Aug;26(4):805-21. French. PMID: 5119131.</ref> | ||
It's mode of action is stated to be ] and it is a ].<ref> Lippmann, W. (1970). "Blockade of noradrenaline uptake and inhibition of gastric acid secretion by 2- imidazoline maleate (Sch-12650)". Journal of Pharmacy and Pharmacology. 22 (5): 387–388. doi:10.1111/j.2042-7158.1970.tb08548.x.</ref> | It's mode of action is stated to be ] and it is a ].<ref> Lippmann, W. (1970). "Blockade of noradrenaline uptake and inhibition of gastric acid secretion by 2- imidazoline maleate (Sch-12650)". Journal of Pharmacy and Pharmacology. 22 (5): 387–388. doi:10.1111/j.2042-7158.1970.tb08548.x.</ref> | ||
Line 66: | Line 66: | ||
</ref> #3 substance:<ref>Lewis A. Walter, US4081544 (1978 to Merck Sharp and Dohme Corp).</ref><ref>Lewis A. Walter, US3932431 (1976 to Merck Sharp and Dohme Corp).</ref> | </ref> #3 substance:<ref>Lewis A. Walter, US4081544 (1978 to Merck Sharp and Dohme Corp).</ref><ref>Lewis A. Walter, US3932431 (1976 to Merck Sharp and Dohme Corp).</ref> | ||
] | ] | ||
The reaction between p-chlorophenylacetonitrile (1) and ] (2) in the presence of a suitable base gives (3). Reaction with ethylenediamine forms the imidazoline ring giving (4). Air oxidation then affords the tertiary carbinol by attack at the highly activated |
The reaction between p-chlorophenylacetonitrile (1) and ] (2) in the presence of a suitable base gives (3). Reaction with ethylenediamine forms the imidazoline ring giving (4). Air oxidation then affords the tertiary carbinol by attack at the highly activated benzylic carbon giving dazadrol (5). | ||
==See also== | |||
*] | |||
== References == | == References == | ||
{{reflist}} | {{reflist}} | ||
Line 72: | Line 74: | ||
{{Antidepressants}} | {{Antidepressants}} | ||
{{Monoamine reuptake inhibitors}} | {{Monoamine reuptake inhibitors}} | ||
] | |||
] | |||
] | |||
{{Drafts moved from mainspace|date=December 2024}} | {{Drafts moved from mainspace|date=December 2024}} |
Latest revision as of 22:09, 19 December 2024
Clinical data | |
---|---|
Other names | Sch 12650 |
Identifiers | |
IUPAC name
| |
CAS Number |
|
ChemSpider | |
Chemical and physical data | |
Formula | C15H14ClN3O |
Molar mass | 287.75 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Dazadrol is an antidepressant first quoted in the literature in 1971.
It's mode of action is stated to be Noradrenaline reuptake inhibitor and it is a gastric acid secretion inhibitor.
Synthesis
Patent (Ex 12): #3 substance:
The reaction between p-chlorophenylacetonitrile (1) and 2-bromopyridine (2) in the presence of a suitable base gives (3). Reaction with ethylenediamine forms the imidazoline ring giving PC20361737 (4). Air oxidation then affords the tertiary carbinol by attack at the highly activated benzylic carbon giving dazadrol (5).
See also
References
- Schmitt H, Petillot N. Propriétés pharmacologiques d'un nouvel antidépresseur potentiel: le ((p-chlorophényl)-2-(pyridyl)-hydroxyméthyl) imidazoline (SCH 12.650 . Therapie. 1971 Jul-Aug;26(4):805-21. French. PMID: 5119131.
- Lippmann, W. (1970). "Blockade of noradrenaline uptake and inhibition of gastric acid secretion by 2- imidazoline maleate (Sch-12650)". Journal of Pharmacy and Pharmacology. 22 (5): 387–388. doi:10.1111/j.2042-7158.1970.tb08548.x.
- Walter Lewis A, DE1905353A1 (1969 to Scherico Ltd).
- Lewis A. Walter, US4081544 (1978 to Merck Sharp and Dohme Corp).
- Lewis A. Walter, US3932431 (1976 to Merck Sharp and Dohme Corp).
Monoamine reuptake inhibitors | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DATTooltip Dopamine transporter (DRIsTooltip Dopamine reuptake inhibitors) |
| ||||||||||||||
NETTooltip Norepinephrine transporter (NRIsTooltip Norepinephrine reuptake inhibitors) |
| ||||||||||||||
SERTTooltip Serotonin transporter (SRIsTooltip Serotonin reuptake inhibitors) |
| ||||||||||||||
VMATsTooltip Vesicular monoamine transporters | |||||||||||||||
Others |
| ||||||||||||||
See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins |